Scholarlink

Objective <p>To evaluate the impact of β-blockers on 28-day and 180-day mortality in ICU patients with malignancies and to assess their effects on tumor-related biomarkers.</p> Methods <p>This study utilized data from the MIMIC-IV database. A doubly robust estimation approach combining propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) was employed to compare mortality outcomes between patients who received β-blockers and those who did not.</p> Results <p>β-blocker use was significantly associated with reduced 28-day (adjusted OR = 0.61, 95% CI: 0.48–0.78, <i>p</i> &lt; 0.001) and 180-day mortality (adjusted OR = 0.69, 95% CI: 0.59–0.84, <i>p</i> &lt; 0.001). Sensitivity analyses confirmed the robustness of these findings. Among the tumor-related biomarkers analyzed, no significant changes were observed in CEA, AFP, CA-125, LDH, or WBC levels, while CRP levels showed a significant decrease.</p> Conclusion <p>β-blockers are associated with a significant reduction in both short-term and long-term mortality in ICU patients with malignancies. However, they appear to have limited effects on tumor-specific biomarkers, with the exception of a potential anti-inflammatory effect reflected by reduced CRP levels.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Beta-Blockers and mortality in patients with malignancy and cardiovascular disease: an analysis of the MIMIC-IV database

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月21日

查看全文
  • Bing-ao Chen,
  • Sheng Lu,
  • Qi-hang Yang,
  • Hong-bao Chen,
  • Yang Yuan

摘要

Objective

To evaluate the impact of β-blockers on 28-day and 180-day mortality in ICU patients with malignancies and to assess their effects on tumor-related biomarkers.

Methods

This study utilized data from the MIMIC-IV database. A doubly robust estimation approach combining propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) was employed to compare mortality outcomes between patients who received β-blockers and those who did not.

Results

β-blocker use was significantly associated with reduced 28-day (adjusted OR = 0.61, 95% CI: 0.48–0.78, p < 0.001) and 180-day mortality (adjusted OR = 0.69, 95% CI: 0.59–0.84, p < 0.001). Sensitivity analyses confirmed the robustness of these findings. Among the tumor-related biomarkers analyzed, no significant changes were observed in CEA, AFP, CA-125, LDH, or WBC levels, while CRP levels showed a significant decrease.

Conclusion

β-blockers are associated with a significant reduction in both short-term and long-term mortality in ICU patients with malignancies. However, they appear to have limited effects on tumor-specific biomarkers, with the exception of a potential anti-inflammatory effect reflected by reduced CRP levels.